Amryt Pharma Plc’s Product AP101 Gets FDA’s Fast Track Designation

  • Amryt Pharma Plc’s (AMYT) product AP101 (Oleogel-S10) investigation has been designated Fast Track development program from the US Food and Drug Administration.
  • AP101 Epidermolysis Bullosa has been recognised by Food and Drug Administration (FDA) as a serious disease with no FDA-approved treatments for this condition.
  • The company has generated preliminary clinical data from an ongoing Phase 3 trial, which as per FDA supports the continued study.
  • On 1st October 2019, at the time of writing, GMT 08:12 AM, AMYT shares were trading at GBX 134.00, up by 3.00 points or 2.29% against the previous day closing price.